title: A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study.
abstract: Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease.
authors.affiliation: McGill University, Montreal, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Baruchel
authors.forename: M
authors.initials: M
authors.lastname: Bernstein
authors.forename: V M
authors.initials: VM
authors.lastname: Whitehead
authors.forename: S
authors.initials: S
authors.lastname: Devine
authors.forename: B
authors.initials: B
authors.lastname: Bell
authors.forename: R
authors.initials: R
authors.lastname: Dubowy
authors.forename: H
authors.initials: H
authors.lastname: Grier
authors.forename: C
authors.initials: C
authors.lastname: Kretschmar
authors.forename: A M
authors.initials: AM
authors.lastname: Langevin
authors.forename: T
authors.initials: T
authors.lastname: Vietti
mesh_terms: D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D005723:gamma-Glutamyltransferase / Q000037:antagonists & inhibitors
chemical_list: D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D007555:Isoxazoles; D005723:gamma-Glutamyltransferase; C006303:acivicin